XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.2
Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)
€ / shares in Units, € in Millions
 6 Months Ended
Jun. 30, 2024
EUR (€)
shares
€ / shares
Restricted Share Plan 2024  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 4,505,145
Fair value of plan at the date of grant | € € 346
Service period 3 years
Restricted Share Plan 2024 | Without market condition  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 2,888,502
Fair value per share awarded (in euros per share) | € / shares € 81.84 [1]
Restricted Share Plan 2024 | With market condition  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 1,616,643
Restricted Share Plan 2024 | With market condition | Excluding General Director  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 1,394,478
Fair value per share awarded (in euros per share) | € / shares € 72.79 [2]
Restricted Share Plan 2024 | With market condition | Chief Executive Officer  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 82,500
Fair value per share awarded (in euros per share) | € / shares € 72.38 [2]
Restricted Share Plan 2024, Additional Shares | With market condition | Excluding General Director  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 139,665
Fair value per share awarded (in euros per share) | € / shares € 13.50 [3]
[1] Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.
[2]
(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.
[3] (c) Additional tranche subject to a higher level of market conditions